palm11-PrRP31 TFA
Based on 1 Customer Validation
palm11-PrRP31 TFA is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 TFA is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 TFA is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 TFA can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction.
For research use only. We do not sell to patients.
- Purity : 99.44%
- Formula: C181H289N55O46S·xC2HF3O2
- Molecular Weight:4003.64 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
Appearance Solid
-
Molecular Weight 4003.64 (free base)
-
Formula C181H289N55O46S·xC2HF3O2
-
Color White to off-white
-
SMILES
O=C(NCCCC[C@@H](C(N[C@@H]([C@H](O)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](C)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@@H](C(C)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC7=CC=CC=C7)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CO)NC([C@H](CC8=CNC=N8)NC([C@H](CCCNC(N)=N)NC([C@H](CC9=CNC=N9)NC([C@H]([C@H](O)C)NC([C@H](CCCNC(N)=N)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC)=O.O=C(O)C(F)(F)F.[x]
-
Sequence
Ser-Arg-Thr-His-Arg-His-Ser-Met-Glu-Ile-{Lys(N-γGlu(N-palm))}-Thr-Pro-Asp-Ile-Asn-Pro-Ala-Trp-Tyr-Ala-Ser-Arg-Gly-Ile-Arg-Pro-Val-Gly-Arg-Phe-NH2
-
Sequence Shortening
SRTHRHSMEI-{Lys(N-γGlu(N-palm))}-TPDINPAWYASRGIRPVGRF-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
H2O : ≥ 100 mg/mL
DMSO : 2 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: ≥ 100 mg/mL; Clear solution
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
palm11-PrRP31 TFA Related Classifications
HY-P10380A Related Classifications
Powered by Bioz